...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Modern Pathology >A mitotically active, cellular tumor stroma and|[sol]|or inflammatory cells associated with tumor cells may contribute to intermediate or high Oncotype DX Recurrence Scores in low-grade invasive breast carcinomas
【24h】

A mitotically active, cellular tumor stroma and|[sol]|or inflammatory cells associated with tumor cells may contribute to intermediate or high Oncotype DX Recurrence Scores in low-grade invasive breast carcinomas

机译：在低度浸润性乳腺癌中，有丝分裂活跃的细胞肿瘤基质和与肿瘤细胞相关的炎性细胞可能有助于中等或较高的癌型DX复发评分

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Oncotype DX is an RT-PCR-based 21-gene assay validated to provide prognostic and predictive information in the form of a Recurrence Score in patients with estrogen receptor-positive, lymph node-negative breast cancer. Although the Recurrence Score was shown to correlate with several histopathological tumor features, there is a significant proportion of cases showing an apparent discrepancy between Recurrence Score and risk estimates based on the traditional clinicopathological tumor features. In this study, we tested whether a proliferating, cellular stroma and/or admixed inflammatory cells may result in an artificially increased Recurrence Score in low-grade invasive breast cancers. We analyzed the histopathological features in 141 low-grade invasive breast carcinomas, including 41 special type (tubular, cribriform and mucinous) carcinomas, with available Recurrence Score. The tumor stroma was evaluated for increased cellularity and presence of inflammatory cells. Double immunohistochemical stains for pancytokeratin and Ki-67 was performed to assess the cell proliferation in tumor vs stromal/inflammatory cells. The clinicopathological features of tumors with Recurrence Score 1 predicted Recurrence Score ≥18 with an area under the curve of 0.8967 on receiver operator curve analysis (P<0.0001). Our results suggest that the presence of increased stromal cellularity and/or associated inflammatory cells in low-grade invasive breast carcinomas may contribute to an apparently increased risk of recurrence according to Oncotype DX Recurrence Score. Careful assessment and correlation with histopathological features in such cases may help in determining the appropriate patient management.
机译：Oncotype DX是一种基于RT-PCR的21基因检测方法，经过验证可通过雌激素受体阳性，淋巴结阴性乳腺癌患者的复发评分形式提供预后和预测信息。尽管显示复发分数与多种组织病理学肿瘤特征相关，但仍有相当一部分病例显示复发分数与基于传统临床病理肿瘤特征的风险估计之间存在明显差异。在这项研究中，我们测试了低度浸润性乳腺癌中增殖的细胞基质和/或混合的炎性细胞是否可能导致人为增加的复发分数。我们分析了141例低度浸润性乳腺癌的组织病理学特征，包括41种特殊类型（小管，筛状和粘液性）癌，并提供了复发评分。评价肿瘤基质的细胞增多和炎性细胞的存在。进行了全细胞角蛋白和Ki-67的双重免疫组织化学染色，以评估肿瘤细胞与基质/炎症细胞之间的细胞增殖。接受者操作者曲线分析显示，复发评分为1的肿瘤的临床病理特征为复发评分≥18且曲线下面积为0.8967（P <0.0001）。我们的结果表明，根据Oncotype DX复发评分，低度浸润性乳腺癌中基质细胞增多和/或相关的炎症细胞的存在可能导致明显增加的复发风险。在这种情况下，仔细评估并与组织病理学特征进行关联可能有助于确定适当的患者管理方式。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号